Tag: Protagonist Therapeutics
Polycythemia vera treatment : Protagonist Therapeutics’ PTG-300 gets FDA ODD
Protagonist Therapeutics has bagged the orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for PTG-300 for polycythemia vera treatment. Polycythemia vera ... Read More
Protagonist Therapeutics raises $22m equity financing from BVF Partners
Protagonist Therapeutics, a US biopharma company, focused on discovering and development of novel peptide-based drugs for patients with significant unmet medical needs, has raised a ... Read More